Sepsis Market

Sepsis Market

DELHI, DELHI, INDIA, June 10, 2024 /EINPresswire.com/ -- DelveInsight's “Sepsis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Explore the intricate details of the Sepsis Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Sepsis Market Forecast. Click here to stay ahead in healthcare innovation @ Sepsis Market Size

Key Takeaways from the Sepsis Market Report
• June 2024:- Cidara Therapeutics Inc.- A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study). The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
• June 2024:- Shionogi- The primary purpose of this study is to understand the pharmacokinetics (PK) of single and multiple doses of cefiderocol in children from birth to less than 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections.
• As per analysis, it is notable that in the 7MM, the majority of patient pool were males as compared to females whereas in the US female population dominated the Sepsis incident pool..
• According to Delveinsight, approximately 57% of all cases were sepsis without organ dysfunction followed by septic shock (24%) and severe sepsis (18%) in the United States in 2023. These cases are expected to increase during the forecast period (2024-2034).
• As per the analysis, lung infection, UTI infection, gut infection, and skin infection are the leading four infection sites in patients with sepsis, accounting for approximately 43%, 30%, 13%, and 13% respectively of all sites of infection.
• The leading Sepsis Companies such as La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.
• Promising Sepsis Pipeline Therapies such as Alirocumab, Imipenem, Cilastatin and Relebactam, Cefiderocol, SBI-101, Ceftobiprole medocaril, VBI-S, and others.

Sepsis Overview
Sepsis is a life-threatening organ dysfunction that results from the body’s response to infection. If not recognized early and managed promptly, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality.

Sepsis Epidemiology Segmentation in the 7MM
• Total Sepsis Incident Cases
• Sepsis Severity-specific Incident Cases
• Sepsis Gender-specific Incident Cases
• Sepsis Origin-specific Incident Cases

Download the report to understand which factors are driving Sepsis Epidemiology trends @ Sepsis Epidemiological Insights

Sepsis Market Insights
Overall, the global as well as 7MM Sepsis therapeutics market is further expected to increase accrediting the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, increasing research activities and upcoming therapies during the forecast period [2024-2034].

Sepsis Market Dynamics
The dynamics of Sepsis treatment market is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel treatment options to combat the existing treatment based unmet needs. Key players, such as Vivacelle Bio, Inotrem SA, and others are involved actively in developing potential treatment scopes.

Sepsis Treatment Market
Sepsis treatment differs depending on the location and origin of the initial infection, the organs involved, and the amount of any damage. As soon as sepsis is detected, it should be treated as a medical emergency as swiftly and efficiently as possible. Sepsis treatment is divided into two categories: antimicrobial treatment and all-purpose supportive treatment. Today, the typical treatment for sepsis consists primarily of aiming to eradicate the focus through interventions such as interventional radiology or surgical techniques for source control, as well as the prompt administration of empirically targeted antibiotics.

Sepsis Therapies and Companies
• Alirocumab: Regeneron Pharmaceuticals
• Imipenem, Cilastatin and Relebactam: Merck Sharp & Dohme LLC
• Cefiderocol: Shionogi Inc.
• SBI-101: Sentien Biotechnologies, Inc.
• Ceftobiprole medocaril: Basilea Pharmaceutical
• VBI-S: Vivacelle Bio

Sepsis Drugs Uptake

• Vivacelle Bio’s lead candidate, VBI-S is made of small particles of specific lipid called micelles and liposomes to treat hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the ’body’s fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. In July 2019, the company announced US FDA clearance to enroll patients into a Phase IIa clinical trial of VBI-S to elevate blood pressure in subjects who have shock due to sepsis. The therapy is currently under Phase II clinical evaluation to treat hypovolemia due to sepsis/septic shock. Furthermore, the company has also intiated a Phase II/III clinical trial for the treatment of Hypotension in Hypovolemic Septic Shock Patients.

• Inotrem’s Nangibotide is a synthetic peptide and first-in-class TREM-1 inhibitor. Nangibotide blocks the TREM-1-mediated immune dysregulations in sterile or infectious acute inflammatory syndromes. The drug restores a balanced inflammatory response and improves outcomes, particularly in those patients with high levels of TREM-1 pathway activation. The drug is currently under Phase II for the treatment of septic shock. This lead candidate has been granted access to the EMA’s PRIority MEdicines (PRIME) scheme, and was also granted Fast-track status by the FDA for septic shock.

Scope of the Sepsis Market Report
• Coverage- 7MM
• Sepsis Companies- La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.
• Sepsis Pipeline Therapies- Alirocumab, Imipenem, Cilastatin and Relebactam, Cefiderocol, SBI-101, Ceftobiprole medocaril, VBI-S, and others.
• Sepsis Market Dynamics: Sepsis Market Drivers and Barriers

Discover more about Sepsis Drugs in development @ Sepsis Ongoing Clinical Trials Analysis

Table of Content
1. Key Insights
2. Executive Summary of Sepsis
3. Competitive Intelligence Analysis for Sepsis
4. Sepsis: Market Overview at a Glance
5. Sepsis: Disease Background and Overview
6. Patient Journey
7. Sepsis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Sepsis Unmet Needs
10. Key Endpoints of Sepsis Treatment
11. Sepsis Marketed Products
12. Sepsis Emerging Therapies
13. Sepsis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Sepsis

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Yash Bhardwaj
DelveInsight
+91 9650213330
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.